NCT02937948
Completed
Not Applicable
Phase II Study of Adaptative Radiotherapy for Locally Advanced Cervical Cancer
ConditionsUterine Cervical Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Uterine Cervical Cancer
- Sponsor
- Center Eugene Marquis
- Enrollment
- 85
- Locations
- 12
- Primary Endpoint
- Number of patient having an Acute genito-urinary (GU) and Gastro-intestinal (GI) toxicities assessed by CTCAE V4.03
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
This study evaluates the effect of adaptative Intensity-Modulated Radiation Therapy (IMRT) in the treatment of locally advanced cervical cancer on acute genito-urinary (GU), and gastrointestinal (GI) toxicities. Every patients will be treated according to the adaptative IMRT strategy.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Cervix carcinoma proved by histology
- •According International Federation of Gynecology and Obstetrics (FIGO) classification, stages IB2, IIA, IIB, IIIA and IIIB without lumbo-aortic lymph node damage (surgical or radiologic)
- •Patient treated with radio-chemotherapy then curietherapy with curative aim, validated in multidisciplinary meeting
- •Renal, hepatic and cardiovascular functions that allow administration of the associated systemic treatment
- •Older than 18 years
- •Good general status, World Health Organization less or equal to 1
- •Signed informed consent
Exclusion Criteria
- •History of cancer that is not controlled and / or treated for less than 5 years (excepted for cutaneous baso-cellular cancer)
- •History of pelvic irradiation
- •Simultaneous participation to another research that could interfere with the study results
- •Pregnant or breastfeeding patient
- •Patient under tutor or guardian
- •Patient not able to respect medical follow-up for geographical, social or psychological reasons
- •Not affiliated to a system of French social security
Outcomes
Primary Outcomes
Number of patient having an Acute genito-urinary (GU) and Gastro-intestinal (GI) toxicities assessed by CTCAE V4.03
Time Frame: 3 months after end of radio-chemotherapy treatment
Secondary Outcomes
- Number of patient having a Grade ≥ 2 Hematologic and other toxicities assessed by CTCAE V4.03(3 months after end of radio-chemotherapy treatment)
Study Sites (12)
Loading locations...
Similar Trials
Unknown
Phase 2
IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal CarcinomaNasopharyngeal NeoplasmsElderlyChemotherapyNCT06688175The First Affiliated Hospital of Xiamen University32
Completed
Phase 2
Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By SurgeryCervical CancerEndometrial CancerNCT00331760Radiation Therapy Oncology Group106
Recruiting
Not Applicable
UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-3 (UNITED-3)Glioblastoma Multiforme, AdultNCT05720078Sunnybrook Health Sciences Centre70
Withdrawn
Phase 2
Intensity-Modulated Radiotherapy for Recurrent Head and Neck CancerCarcinoma of the Head and NeckNCT00257335Nilam Ramsinghani
Recruiting
Not Applicable
Pelvis Adaptive Radiotherapy (ART)Pelvis NeoplasmsNCT06650033Royal North Shore Hospital280